AtriCure, Inc.
6033 Schumacher Park Drive
West Chester
Ohio
45069
United States
Tel: 513-755-4100
Fax: 513-755-4108
Website: http://www.atricure.com/
Email: info@atricure.com
325 articles about AtriCure, Inc.
-
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results
2/15/2024
AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management and post-operative pain management, announced fourth quarter 2023 and full year 2023 financial results.
-
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference
1/25/2024
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024.
-
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2023, Provides Financial Outlook for 2024
1/8/2024
AtriCure, Inc. announced preliminary financial results for the fourth quarter and full year 2023 and provided 2024 financial guidance.
-
AtriCure Appoints Shlomi Nachman to the Board of Directors
1/4/2024
AtriCure, Inc. today announced it appointed Shlomi Nachman to its Board of Directors.
-
AtriCure to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
12/20/2023
AtriCure, Inc. today announced that the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference.
-
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference
11/15/2023
AtriCure, Inc. today announced that the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference.
-
AtriCure Releases 2023 ESG Report
11/14/2023
AtriCure, Inc. today announced that the company has published its 2023 Environmental, Social and Governance (ESG) Report highlighting the company’s corporate responsibility and sustainability initiatives.
-
AtriCure to Announce Third Quarter 2023 Financial Results
10/11/2023
AtriCure, Inc. today announced that it will release its third quarter 2023 financial results on Wednesday, November 1, 2023.
-
AtriCure Reports Second Quarter 2023 Financial Results
7/25/2023
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2023 financial results.
-
AtriCure to Participate at Upcoming Investor Conferences - July 21, 2023
7/21/2023
AtriCure, Inc. today announced that the company will be participating in two upcoming investor conferences.
-
AtriCure to Announce Second Quarter 2023 Financial Results
7/3/2023
AtriCure, Inc. today announced that it will release second quarter 2023 financial results on Tuesday, July 25, 2023.
-
AtriCure Reports First Quarter 2023 Financial Results
5/2/2023
AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management and post-operative pain management, announced first quarter 2023 financial results.
-
AtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education Webcast
4/19/2023
AtriCure, Inc. today announced that the company will be hosting an investor education webcast in conjunction with Canaccord Genuity, focusing on Cryo Nerve Block Therapy.
-
AtriCure to Announce First Quarter 2023 Financial Results
4/11/2023
AtriCure, Inc. today announced that it will release first quarter 2023 financial results on Tuesday, May 2, 2023.
-
AtriCure to Participate in the 22nd Annual Needham Virtual Healthcare Conference
4/3/2023
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference.
-
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results
2/21/2023
AtriCure, Inc., a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management and post-operative pain management, announced fourth quarter 2022 and full year 2022 financial results.
-
AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference
2/17/2023
AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, announced that the company will be participating in the upcoming Oppenheimer 33rd Annual Healthcare Conference.
-
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
1/31/2023
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the first patient was treated in the Left Atrial Appendage Exclusion for Stroke Prevention (LeAAPS™) clinical trial (NCT 05478304).
-
AtriCure to Announce Fourth Quarter and Full Year 2022 Financial Results and Participate in 2023 BTIG Medical Technology Conference
1/24/2023
AtriCure, Inc. today announced that it will release its fourth quarter and full year 2022 financial results on Tuesday, February 21, 2023.
-
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2022, Provides Financial Outlook for 2023
1/9/2023
AtriCure, Inc. announced preliminary financial results for the fourth quarter and full year 2022 and provided 2023 financial guidance.